Cynata Therapeutics Limited

Cynata Therapeutics Limited is a clinical-stage biotechnology company focused on the development and commercialization of innovative stem cell and regenerative medicine therapies. The company’s proprietary Cymerus platform leverages induced pluripotent stem cell (iPSC) technology to produce mesenchymal stem cells for potential human therapeutic use. Cynata’s lead product candidates target a range of serious medical conditions, including graft versus host disease, osteoarthritis, and diabetic wounds, with several candidates in active clinical trials. The company also collaborates with global partners such as Fujifilm to advance manufacturing and supply capabilities. Cynata Therapeutics Limited is listed on the CHI-X Market Australia – Limit Venue, providing investors access to its shares through this alternative trading platform. Headquartered in Cremorne, Australia, and incorporated in 2003, the company plays a significant role in advancing regenerative medicine and addressing unmet clinical needs in the global healthcare sector.